ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY. SJHR-Africa [Internet]. 2023 Dec. 7 [cited 2026 Jul. 24];4(12):5. Available from: https://sjhrafrica.org/index.php/public-html/article/view/865